AzTrials
AzTrials

AnalgesiaPhase 4NCT04116554

Bilateral Transversus Thoracic Muscle Plane Block as Analgesic in Open Heart Surgeries by US.

A Phase 4 study testing 0.25% bupivacaine. and 0.9%saline in people with Analgesia, run by Fayoum University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

OPEN CARDIAC SURGERY may cause severe postoperative pain and promote a high risk of chronic pain if not treated adequately, that is caused by multiple factors; sternotomy, costotransverse and costovertebral joint distensions, opening of the pericardium, internal mammarian artery harvesting, surgical manipulation of… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Analgesia
What is being tested?
0.25% bupivacaine. and 0.9%saline
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
70 participants
Where
1 siteEgypt
Study dates
27 Dec 2019to 1 Feb 2021
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patients 18 years of age or older (18 - 80 yrs. old).
  • Scheduled for elective cardiac surgery for valve replacement or adult congenital (VSD or ASD) via median sternotomy.

Who cannot join

  • Patients with emergency surgeries.
  • Allergy to drug used.
  • re-do surgery.
  • Coagulopathy.
  • Neuromuscular disease.
  • Preoperative poor left ventricular function (EF < 35%).
Show all 9Show fewer
  • Systemic infections or infections at site of injection.
  • Psychiatric illnesses (schizophrenia, bipolar, uncontrolled anxiety or depression).
  • Narcotic dependency.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Fayoum University Hospital

    Al Fayyum, 63511

Other trials in Egypt

About this study

Official title: Efficacy of Ultrasound-guided Bilateral Transversus Thoracic Muscle Plane Block as Postoperative Analgesia in Adult Patients Undergoing Open Heart Surgeries: a Randomized Controlled Study.

OPEN CARDIAC SURGERY may cause severe postoperative pain and promote a high risk of chronic pain if not treated adequately, that is caused by multiple factors; sternotomy, costotransverse and costovertebral joint distensions, opening of the pericardium, internal mammarian artery harvesting, surgical manipulation of the parietal pleura, chest tube insertion and other musculoskeletal trauma that occurs during surgery.

Adequate analgesia is important not only for patient comfort, but for weaning from ventilator and prevention of respiratory complications. Opioids are used to provide analgesia, but they are associated with significant side effects which include sedation, respiratory depression, nausea, and vomiting.

Read more

Severe sternotomy pain in cardiac surgery has been reported in up to 49% of patients at rest and 78% at movement. Of the various options for postoperative pain relief in cardiac surgery, we have chosen an ultrasound-guided transversus thoracic muscle plane (TTP) block versus sham block performed by the anesthesiologist.

Transversus thoracic muscle plane (TTP) block and The pecto-intercostal fascial plane block can block multiple anterior branches of the intercostal nerves (T2 to 6), which dominate the internal mammary region with a single injection bilaterally.

Read the detailed description

After approval of the institutional ethics committee and written informed consent, (70) patients scheduled for open heart surgery including valve replacement or adult congenital (ASD or VSD) in Fayoum university hospital from May 2019 to November 2020 will be enrolled in this randomized prospective double blinded study.

Patients will be divided into two groups randomized by computer generated random numbers that will be placed in separate opaque envelopes that will be opened by study investigators just before the block.Neither the participants, the study investigators, the attending clinicians, nor the data collectors will be aware of groups' allocation until the study end. The Consolidated Standards of Reporting Trials (CONSORT) recommendations for reporting randomized, controlled clinical trials will be followed.

Group A which will have an ultrasound-guided bilateral transversus thoracic muscle plane (TTP) block.

Group B which will have sham block bilaterally. All patients will be preoperatively examined and investigated by complete blood count, coagulation profile, renal and kidney functions and electrolytes. Electrocardiography, chest x ray and echocardiography will be routinely done. Coronary angiography and carotid arterial duplex will be requested on demand.

Patient will be premedicated by intramuscular injection of 10mg morphine at morning of the operation. Before induction of anesthesia, a five-lead electrocardiography system will be applied to monitor heart rate, rhythm, and ST segments (leads II and V5). A pulse oximeter probe will be attached, and a peripheral venous cannula will be placed. For measurement of arterial pressure and blood sampling, a 20 G cannula will be inserted into either right or left radial artery under local anesthesia. After pre-oxygenation, general anesthesia will be induced by midazolam 2-5 mg, fentanyl (10μg/kg), propofol (3-4mg/Kg), followed by atracurium (0.5 mg/kg).

Trachea will be intubated; patients will be mechanically ventilated with oxygen in air so as to achieve normocarbia. This will be confirmed by radial arterial blood gas analysis and capnogram. An esophageal temperature probe and a Foley catheter will also be placed.

For drug infusion, a triple-lumen central venous catheter will be inserted via the right internal jugular vein.

Anesthesia will be maintained by inhaled Isoflurane 0.4 to 1% and atracurium infusion at a rate of 0.5 mg/kg/h for continued muscle relaxation. During extracorporeal circulation, patients will receive propofol infusion at a rate of 50-100 µ/kg/min. in addition to atracurium infusion.

Before initiation of cardiopulmonary bypass (CPB), the patients will receive intravenous heparin (300-500 units/kg body weight) to achieve an activated clotting time >480s. CPB will be instituted via an ascending aortic cannula and a two-stage right atrial cannula. Before, during (pump blood flow: 2.4l/min/m2), and after CPB, mean arterial pressure will be adjusted to exceed 60mmHg. Cardiac arrest will be induced with cold ante-grade blood cardioplegia. Lactate-enriched Ringer's solution will be added to the CPB circuit to maintain reservoir volume when needed, and packed red blood cells will be added when hemoglobin concentration decrease to less than 7g/dl.

After rewarming the patient to 37°C and separation from CPB; reversal of heparin by protamine sulfate (1:1), and sternal closure will be achieved. The study solution (bupivacaine 0.25% or normal saline will be prepared in the operating room by anesthesiology intern). For carrying out either block bilaterally the skin on either side of the sternum will be prepared with povidone iodine solution. Then a linear ultrasound probe (Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID: 1385, Nile medical center, service@nilemed.net) will be placed on the right and left sides at 3cm from the midsternum. On the surface plane, the subcutaneous tissue is identified, in the intermediate plane, the pectoralis major muscle, the intercostal muscles and the ribs, and in the deep plane the transverse thoracic muscle, the pleura and the lungs.

Group A: will have an ultrasound-guided bilateral transversus thoracic muscle plane (TTP) block. After identification of the anatomical plane between the internal intercostal and the transversus thoracic muscles a 22-gauge short bevel needle (Spinocan, B. Braun Melsungen AG, Germany) will be inserted between the fourth and fifth ribs connecting at the sternum.

Correct needle placement will be confirmed by visualizing the needle in plane along its entire length and the tip of the needle between both muscles, then1 ml of anesthetic liquid will be introduced after confirming a negative aspiration. Appropriate injection to accomplish the TTP block will be indicated by Local anesthetic spread deep to the costal cartilages and downward displacement of the pleura. The TTP blocks will be administered by injection of 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side.

Group B: will have sham block bilaterally. The same technique of TTP block will be used to do sham block on either sides of the chest. 20 ml of 0.9%saline will be injected on each side.

Tracheal extubation will be performed when the patient met the following criteria: awake/arousable, hemodynamically stable, no active bleeding, warm peripheries, and satisfactory arterial blood gas with an FIO2 < 0.5, pressure support on ventilator reduced to 10 Cm H2O, Positive End Expiratory Pressure 5-7 CmH2O, no electrolyte abnormalities, minimal inotropic support, or no escalation in inotropic support.

Postoperative analgesia in ICU will be carried out for both groups with the conventional way by the intensivest using opioids (fentanyl), and the total 24 h. opioid consumption will be recorded.

Measured parameters:

The primary outcome is Total opioid (fentanyl) consumption (time frame: from the time of ICU admission up to 24 h).

Secondary outcomes will include:

  1. VAS score for sternal pain both during rest and with cough (ranging from 0 indicating no pain to 10 indicating extreme pain) judged by objective pain score (table: 1) measured at time intervals: 30 minutes, 1h., 3h.,6h.,12h., and 24h.
  2. Time to extubation (time frame: from the time of ICU admission up to 24 h).
  3. Patient satisfaction (measured as poor, good or excellent).
  4. Hemodynamic variables (HR, SaO2, MABP and inotropic support). (Time frame: from the time of ICU admission up to 24 h).
  5. Nausea and vomiting.
  6. Other complications including; infection, hematoma or local anesthetic toxicity.
  7. ICU length of stay (Time frame: from the time of ICU admission up to discharge to the ward).
  8. Total length stay of hospital (in days).

STATISTICAL ANALYSIS AND SAMPLE SIZE ESTIMATION:

Sample size was calculated using (G power version 3). Minimal sample size of patients was 31 in each group needed to get power level 0.90, alpha level 0.05 and 30% as a difference between the two groups in the morphine consumption after the intervention. To overcome problem of loss of follow up, calculated sample size was increased by 10% to reach 35 in each group.

Conditions
Analgesia
Being tested
0.25% bupivacaine., 0.9%saline
Keywords
transversus thoracic muscle plane block., analgesic after open heart surgery.
Medical subject headings
Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 0.25% bupivacaine.Drug

    Also called plain marcaine

    20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side

  • 0.9%salineDevice

    20 ml of 0.9%saline will be injected on each side

Study groups in NCT04116554
Study groupRoleWhat they receive
intervention group (A)Active comparatorwhich will have an ultrasound-guided bilateral transversus thoracic muscle plane (TTP) block by injection of 20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side.
Receives: Drug: 0.25% bupivacaine.
control group (B)Sham comparatorwhich will have sham block bilaterally by injection of 20 ml of 0.9%saline will be injected on each side.
Receives: Device: 0.9%saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total opioid consumption

    the amount of opioid (mostly used is fentanyl amp. in equivalent doses ) that has been used for 24 hours after admission in ICU

    Measured: from the time of ICU admission hour 1 up to 24 hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Oct 2019
  2. Study start27 Dec 2019
  3. Primary completion31 Jan 2021
  4. Study completion1 Feb 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04116554
Sponsor's protocol ID
D199
Status last verified
Feb 2021
First submitted
2 Oct 2019
Last updated
2 Feb 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Bignami E, Castella A, Allegri M. Postoperative Pain After Cardiac Surgery: An Open Issue. J Cardiothorac Vasc Anesth. 2018 Feb;32(1):e24-e25. doi: 10.1053/j.jvca.2017.09.022. Epub 2017 Sep 20. No abstract available.

    PubMed 29217242
  • Landoni G, Isella F, Greco M, Zangrillo A, Royse CF. Benefits and risks of epidural analgesia in cardiac surgery. Br J Anaesth. 2015 Jul;115(1):25-32. doi: 10.1093/bja/aev201.

    PubMed 26089444
  • Lahtinen P, Kokki H, Hynynen M. Pain after cardiac surgery: a prospective cohort study of 1-year incidence and intensity. Anesthesiology. 2006 Oct;105(4):794-800. doi: 10.1097/00000542-200610000-00026.

    PubMed 17006079

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing 0.25% bupivacaine. and 0.9%saline in people with Analgesia, run by Fayoum University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total opioid consumption (time frame: from the time of ICU admission hour 1 up to 24 hour). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04116554, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in